Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845364 | 0.84 | LMNA (0.52) | LMNAPTPN2PTPN1PTPN6TP53 | |
| SCHEMBL4527081 | 0.84 | HDAC8 (0.60) | LMNAPTPN2PTPN1PTPN6HDAC8 | |
| SCHEMBL4525955 | 0.84 | HDAC8 (0.60) | LMNAPTPN2PTPN1PTPN6HDAC8 | |
| SCHEMBL30681423 | 0.79 | PTPN1 (0.46) | LMNAPTPN1 | |
| SCHEMBL17931067 | 0.78 | LMNA (0.52) | LMNATP53 | |
| SCHEMBL22673082 | 0.78 | LMNA (0.44) | LMNA | |
| SCHEMBL23885434 | 0.76 | LMNA (0.43) | LMNATP53 | |
| SCHEMBL23885571 | 0.76 | LMNA (0.43) | LMNATP53 | |
| SCHEMBL7902824 | 0.76 | KCNQ1 (0.53) | LMNANPC1 | |
| SCHEMBL2827018 | 0.75 | DRD2 (0.51) | LMNAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| CN-101253152-A | Amide derivatives as ROCK inhibitors | ASTELLAS PHARMA INC (JP) | 2008-08-27 | — | — | CN | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | LMNA 3083/4885PTPN2 1253/4885PTPN1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.